No perspectives yet — be the first!
Be the first verified clinician to share a view on Eptifibatide.
100% anonymous · NPI-verifiedFDA status last checked Nov 11, 2026
A cyclical heptapeptide with anticoagulant activity. Eptifibatide selectively and reversibly binds to and blocks the platelet glycoprotein IIb/IIIa receptor.
Eptifibatide
Approved by the FDA.
Tested in at least one proper controlled study in people, with results.
No brand records are linked yet.
How it works. Proven facts and ideas still being studied are kept apart.
Not yet reviewed.
Tested in at least one proper controlled study in people, with results.
FDA-approved. Applications: NDA020718.
Last verified: Nov 11, 2026
Share your perspective on Eptifibatide and help peers make informed prescribing decisions.
Your 45-second perspective helps thousands of colleagues.
Your real-world insights guide colleagues
Your identity stays private — only specialty/region shown
Compare your perspective to specialty peers
